BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Has Average Target Price of $31.38 According to Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a consensus rating of “Hold” from the eleven brokerages that are covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $31.38.

A number of brokerages have commented on BLFS. HC Wainwright downgraded BioLife Solutions from a “buy” rating to a “neutral” rating and decreased their target price for the company from $32.00 to $31.00 in a research note on Thursday, July 23rd. Jefferies Financial Group cut BioLife Solutions from a “buy” rating to a “hold” rating and increased their price target for the stock from $30.00 to $31.00 in a research report on Thursday, July 23rd. Benchmark downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings upgraded BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Finally, William Blair set a $31.00 price objective on BioLife Solutions in a research note on Thursday, July 23rd.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $38.61 on Monday. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.82. BioLife Solutions has a 1-year low of $17.86 and a 1-year high of $39.76. The company’s fifty day moving average is $36.08 and its two-hundred day moving average is $28.50.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, beating the consensus estimate of $0.03 by $0.88. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. The business had revenue of $28.47 million during the quarter, compared to analyst estimates of $27.80 million. Sell-side analysts expect that BioLife Solutions will post 0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the company. Tidal Investments LLC bought a new stake in BioLife Solutions in the 2nd quarter valued at about $819,000. WINTON GROUP Ltd bought a new position in BioLife Solutions in the 2nd quarter worth about $201,000. Engineers Gate Manager LP bought a new position in BioLife Solutions in the 2nd quarter worth about $424,000. Squarepoint Ops LLC acquired a new stake in shares of BioLife Solutions in the second quarter valued at approximately $3,754,000. Finally, AXQ Capital LP acquired a new stake in shares of BioLife Solutions in the second quarter valued at approximately $203,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc is a life sciences technology company that develops and supplies products used to preserve, store, process and transport cells and tissues. Its solutions support the development and commercialization of cell and gene therapies, as well as other biological materials that require controlled temperature and handling conditions.

The company’s product portfolio includes biopreservation media such as CryoStor and HypoThermosol, cryogenic storage bags and containers, controlled-rate freezing systems, automated thawing equipment and related laboratory tools.